Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Teams with Agilent to Develop ChIP Kits for Epigenetics

NEW YORK (GenomeWeb News) – Millipore said today that it will work with Agilent Technologies to develop chromatin immunoprecipitation kits for the epigenetics research market.
The collaboration will involve teaming Millipore’s knowledge in ChIP kits, reagents, and antibodies with Agilent’s microarray and data analysis solutions, the Billerica, Mass.-based Millipore stated.
The aim is to use these combined technologies to create kits that will improve researchers’ productivity and streamline genetic analysis studies, the companies said.
“We expect to help epigenetics researchers minimize the barriers of entry into chromatin state mapping, readily obtain reproducible genomic profiling data, and overcome the traditional challenges of ChIP assays," said Geoffrey Crouse, VP of Millipore's life science strategic business unit.
Agilent developed its microarray-based ChIP-on-chip technology after its 2005 acquisition of Computational Biology Corporation.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.